UroGen Pharma (URGN) 8-K UroGen Pharma Reports Second Quarter 2019 Financial Results and Recent

Exhibit 99.1

UroGen Pharma Reports Second Quarter 2019 Financial Results and Recent

Corporate Developments

UGN-101 Rolling NDA Submission on Track for Q4 2019 with Planned Launch in 1H 2020

Final ToplineUGN-101 Phase 3 Data from OLYMPUS Trial to be Announced in Q3 2019

Company Investor Day Scheduled for September 24, 2019

Quarterly Conference Call and Webcast to be Held on Monday, August 12, 2019 at 8:30 AM ET

NEW YORK, August 9, 2019—UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced financial results for the second quarter ended June 30, 2019 and provided an overview of the Company’s recent developments.

“Our team has continued to make significant progress on key initiatives during the second quarter, including the submission of the CMC modules to our rolling New Drug Application (NDA) forUGN-101. We have locked the database on our Phase 3 OLYMPUS study and are on track to complete the submission in Q4 as we prepare for a potential approval and launch in the first half of 2020,” said Liz Barrett, President and Chief Executive Officer of UroGen. “We are confident that our account-based commercial strategy will allow for seamless adoption and integration into urology practices following anticipated approval. We look forward to sharing further details aboutUGN-101 commercial preparations, ongoing clinical programs, and new developments at our Investor Day on September 24, 2019.”

Recent Highlights and Upcoming Milestones

• UGN-101 Clinical Development:

• UroGen recently submitted the CMC modules to the rolling NDA for investigational agentUGN-101 for the treatment of patients withlow-grade upper tract urothelial cancer (LG UTUC). Completion and acceptance of the Company’s rolling NDA submission remains on track for 2H 2019. If approved, the Company expects to launchUGN-101 in the United States in 1H 2020. It would be the first medicine approved for this unique, orphan indication.

• At the 114^th American Urological Association (AUA) Annual Meeting in Chicago, a presentation in the plenary session highlighted findings from a secondary analysis from the pivotal Phase 3 OLYMPUS trial which demonstrated the unmet need and potential forUGN-101 to transform the treatment paradigm for patients with LG UTUC.

• The Company expects to announce updated Phase 3 data from the OLYMPUS trial at its upcoming Investor Day on September 24, 2019.

• Pipeline Advancement:

• UGN-102:

• The Company continues to enroll patients in its Phase 2b OPTIMA II clinical trial of investigational agentUGN-102 (mitomycin gel) for intravesical instillation as a first line-chemoablation agent in the treatment of patients with intermediate risklow-gradenon-muscle invasive bladder cancer (LG NMIBC), a form of disease associated with a high risk of recurrence.UGN-102 has the potential to address an unmet need for the approximately 80,000 patients with intermediate risk LG NMIBC.

• The OPTIMA II trial is enrolling ahead of schedule, and the company plans to present early complete response data on a portion of patients at its upcoming Investor Day on September 24, 2019.

• If approved,UGN-102 would represent a novel advance in the treatment of recurrentnon-muscle invasive bladder cancer, as there are currently no drugs approved by the FDA as first-line treatment for LG NMIBC.

• UGN-201:

• The Company is developing investigational agentUGN-201, a TLR7/8 immunomodulatory agent for the treatment of high-grade bladder disease. UroGen is exploring the utility ofUGN-201 in the context of novel combinatorial immunotherapy for NMIBC.

• Commercial Preparations:

• UroGen has made considerable progress to accelerate educational initiatives to drive awareness of the significant unmet need for patients with LG UTUC where current SOC is kidney removal. Little education and support have previously been available for patients and stakeholders and UroGen is in a unique position to lead in this space. Thesepre-commercial activities and infrastructure build out will help to reinforce rapid adoption and seamless integration ofUGN-101 into urology practices following anticipated regulatory approval.

• In conjunction with the Company’s educational efforts, UroGen is also engaging in a proactive market access strategy to define the cost burden to the system for LG UTUC via an HEOR study.

• Corporate:

• Robert G. Uzzo, M.D., FACS, Chair of the Department of Surgical Oncology at Fox Chase Cancer Center in Philadelphia, PA, has joined UroGen as a special advisor working closely with UroGen’s Medical Affairs team. Dr. Uzzo is well-known as a key opinion leader in the field of urological oncology and has made important clinical and scientific contributions to the field.

• In the second quarter, UroGen entered into an agreement with Janssen Research & Development, LLC (Janssen) to conduct an early-stage feasibility evaluation in a therapeutic area of mutual interest. UroGen and Janssen will each conduct certain activities under the terms of the agreement.

• The Company will host a live webcast in conjunction with its Investor Day taking place on Tuesday, September 24^th at 10:00AM Eastern Time in New York, NY.

Second Quarter 2019 Financial Results; 2019 Guidance

• As of June 30, 2019, cash, cash equivalents and marketable securities totaled $233.3 million.

• Research and development expenses for the three months ended June 30, 2019 were $10.0 million, includingnon-cash share-based compensation expense of $2.0 million. Research and development expenses for the six months ended June 30, 2019 were $19.7 million, includingnon-cash share-based compensation expense of $4.3 million.

• General and administrative expenses for the three months ended June 30, 2019 were $13.8 million, includingnon-cash share-based compensation expense of $5.2 million. General and administrative expenses for the six months ended June 30, 2019 were $26.5 million, includingnon-cash share-based compensation expense of $10.3 million.

2

• The Company reported a net loss of $22.5 million, or basic and diluted net loss per ordinary share of $1.08, for the three months ended June 30, 2019. The Company reported a net loss of $43.9 million, or basic and diluted net loss per ordinary share of $2.19, for the six months ended June 30, 2019.

• The 2019 financial guidance set forth during the Company’syear-end earnings call on February 28, 2019 remains the same based on current business goals and anticipated activities.

Conference Call & Webcast Information

Members of UroGen’s management team will host a live conference call and webcast on Monday, August 12, 2019 at 8:30 am Eastern Time to review the Company’s financial results and provide a general business update.

The live webcast can be accessed by visiting the Investors section of the Company’s website athttp://investors.urogen.com. Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (888)771-4371 (U.S.) or (847)585-4405 (International) to listen to the live conference call. The conference ID number for the live call will be 48773603. An archive of the webcast will be available for two weeks on the Company’s website.

3

UROGEN PHARMA LTD.

CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands, except share and per share data)

(Unaudited)

	June 30,		December 31,
	2019		2018
Assets
CURRENT ASSETS:
Cash and cash equivalents	$	90,424	$	101,318
Marketable Securities		98,739		—
Restricted deposit		307		253
Prepaid expenses and other current assets		1,724		672
TOTAL CURRENT ASSETS		191,194		102,243
NON-CURRENT ASSETS:
Property and equipment, net		909		948
Restricted deposit		55		51
Marketable Securities		43,851		—
Othernon-current assets		2,557		317
TOTAL ASSETS	$	238,566	$	103,559
Liabilities and Shareholders’ equity
CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	7,071	$	8,540
Employee related accrued expenses		3,706		4,925
Other current liabilities		1,067		—
TOTAL CURRENT LIABILITIES		11,844		13,465
NON-CURRENT LIABILITIES:
Long-term lease liability		1,943		—
TOTALNON-CURRENT LIABILITIES		1,943		—
TOTAL LIABILITIES		13,787		13,465
TOTAL SHAREHOLDERS’ EQUITY		224,779		90,094
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	238,566	$	103,559

4

UROGEN PHARMA LTD.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(U.S. dollars in thousands, except share and per share data)

(Unaudited)

	Three months ended June 30,							Six months ended June 30,
	2019				2018			2019			2018
REVENUES		18			$	364			18		$	845
COST OF REVENUES		—				318			—			748
GROSS PROFIT		18				46			18			97
OPERATING EXPENSES:
Research and development expenses		9,996				8,273			19,722			15,895
General and administrative expenses		13,775				10,207			26,482			16,276
OPERATING LOSS		(23,753	)			(18,434	)		(46,186	)		(32,074	)
FINANCE INCOME, NET		1,276				408			2,265			766
REALIZED LOSS ON SALE OF SHORT-TERM INVESTMENT		—		��		—			—			(100	)
NET LOSS	$	(22,477	)		$	(18,026	)	$	(43,921	)	$	(31,408	)
NET LOSS PER ORDINARY SHARE, BASIC AND DILUTED	$	(1.08	)		$	(1.14	)	$	(2.19	)	$	(2.02	)
WEIGHTED AVERAGE SHARES OUTSTANDING, BASIC AND
DILUTED		20,833,671				15,784,393			20,095,174			15,528,826
STATEMENT OF COMPREHENSIVE LOSS
NET LOSS	$	(22,477	)		$	(18,026	)	$	(43,921	)	$	(31,408	)
OTHER COMPREHENSIVE INCOME:
UNREALIZED GAIN ON MARKETABLE SECURITIES		281				—			281			—
COMPREHENSIVE LOSS	$	(22,196	)		$	(18,026	)	$	(43,640	)	$	(31,408	)

About UroGen Pharma Ltd.UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical company developing advancednon-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel^™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s lead investigational candidates,UGN-101 (mitomycin gel) for instillation, andUGN-102 (mitomycin gel) for intravesical instillation, are designed to potentially ablate tumors bynon-surgical means and to treat several forms ofnon-muscle invasive urothelial cancer, includinglow-grade upper tract urothelial cancer andlow-gradenon-muscle invasive bladder cancer, respectively. UroGen is headquartered in New York, NY with operations in Los Angeles, CA and Israel.

Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: plans with Janssen to conduct an early stage feasibility evaluation in an area of mutual interest; the potential ofUGN-101 for LG UTUC; the timing for completion of the rolling NDA forUGN-101; the anticipated timing for full Phase 3 data from the OLYMPUS trial; the potential approval ofUGN-101 and the timing thereof; the expectation thatUGN-101, if approved, will be the first drug approved for thenon-surgical treatment of LG UTUC; the timing for completion ofpre-commercial activities and infrastructurebuild-out in anticipation of a potential commercial launch ofUGN-101; the expected readiness of UroGen for a potential commercial launch ofUGN-101 in 1H 2020 and the strength and timing of the potential commercial launch ofUGN-101; the potential of UroGen’s proprietary RTGel^™ technology platform

5

to improve therapeutic profiles of existing drugs; the anticipated timing for enrollment and initial data from the OPTIMA II trial; the opportunity and potential ofUGN-102 for LG NMIBC; and UroGen’s 2019 financial guidance. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the timing and success of clinical trials, including the OLYMPUS Phase 3 trial and the OPTIMA II Phase 2b trial and potential safety and other complications thereof; the ability to obtain regulatory approval within the timeframe expected, or at all; the ability to maintain regulatory approval; complications associated with achieving commercial readiness for the launch of a new product; the labeling for any approved product; the scope, progress and expansion of developing and commercializing UroGen’s product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereofvis-à-vis alternative therapies; risks that UroGen’s net loss for 2019 may differ materially from the anticipated range previously provided by UroGen and affirmed in this press release due to changes in UroGen’s operating plans and/or due to estimates that may prove to be incorrect; and UroGen’s ability to attract or retain key management, members of the board of directors and personnel. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Form10-Q filed with the SEC on the date hereof and other filings that UroGen makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.

UROGEN CONTACT:

Kate Bechtold

Senior Director, Investor Relations

Kate.Bechtold@urogen.com

914-552-0456

6